The Business Times
business-time-50

GSK

Companies & Markets

GSK launches US$2.5 billion savings drive to boost drug pipeline

2026-07-28T11:42:25.000Z
This marks a significant expansion of GSK’s cancer portfolio, which has been slowly growing since it returned to the disease space in 2019.
Consumer & Healthcare

GSK to buy Nuvalent for US$10.6 billion to expand in cancer drugs

2026-06-09T09:05:48.000Z
The data gives momentum to GSK’s fast-growing oncology business.
Companies & Markets

GSK sees blockbuster potential in targeted cancer therapy after promising early data

2026-04-12T14:39:59.000Z
In September 2025, GSK said that Luke Miels (above) would replace Emma Walmsley as chief executive officer.
Consumer & Healthcare

GSK profit lifted by HIV, asthma drugs in boost to new CEO

2026-02-04T15:13:45.000Z
GSK said it will pay US$1.2 billion upfront for the drug, called efimosfermin, with potential for additional milestone payments totalling US$800 million.
Companies & Markets

GSK to buy liver disease drug for as much as US$2 billion

2025-05-14T08:39:14.000Z
Sensodyne maker Haleon has agreed to buy back 44 million shares from Pfizer (top), currently its largest shareholder, with 618 million shares being sold to institutional investors.
International

Pfizer sells entire Haleon stake for US$3.24 billion

2025-03-19T08:27:03.000Z
GSK boosted its 2031 sales forecast to over £40 billion, up from the more than £38 billion it previously expected.
Consumer & Healthcare

GSK plans £2 billion share buyback, boosts long-term outlook

2025-02-05T08:32:32.000Z
Investors are concerned about GSK’s pipeline and recent lower-than-expected sales of its RSV and shingles vaccines.
Companies & Markets

GSK to buy US cancer biotech IDRx for up to US$1.15 billion

2025-01-13T09:45:09.000Z
GSK expects to record a £1.8 billion charge in its third quarter results due to the settlements, with no impact on its investment plans.
Consumer & Healthcare

GSK surges 6.5% after US$2.2 billion Zantac lawsuits settlement

2024-10-10T08:39:49.000Z
The over-the-counter treatment, known also by its non-commercial name ranitidine, was manufactured by several rivals including the French group Sanofi and US drugmaker Pfizer before it was withdrawn in 2019.
Consumer & Healthcare

GSK wins latest US litigation over Zantac drug saga

2024-08-16T11:19:45.000Z
Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More